220 Stocks to Sell Today
Free Report for Zacks.com
Visitors Only

Overall, Zacks Rank #5 Strong Sells perform 6X worse than the market. Are any of these portfolio killers lurking among the stocks you're holding or considering? Find out today for free.


No cost, no obligation to buy anything ever.
Privacy Policy
Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/19/2013

Company Name Symbol %Change
SONIC FOUNDR SOFO
4.40%
SUPPORTCOM I SPRT
3.75%
UNISYS CORP UIS
3.31%
SHORETEL INC SHOR
3.22%
GREEN MOUNTA GMCR
3.13%

Merge Healthcare (MRGE)

by Zacks Equity Research

May 23, 2011 | Comments : 0 Recommended this article: (0)
RGS

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Merge Healthcare's (MRGE) first quarter 2011 adjusted EPS of $0.03 was below the year-ago quarter's $0.05. The company also experienced a 950 bps contraction in gross margin.

Moreover, Merge has improved its sales force, but as a result, operating margin was down by 196 bps. Furthermore, the company's increased interest expense affected its bottom line during the quarter.

Although there is immense potential in the diagnostic imaging market, we remain concerned about the competitive scenario and macro economic headwinds. Consequently we downgrade Merge to Underperform.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.